RSV Resolve Ventures Inc

NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES

Immunovaccine Inc. ("Immunovaccine" or "IMV") (TSX VENTURE:IMV), a clinical
stage vaccine company, has closed the previously announced private placement of
its securities, raising gross proceeds of $1,603,880. Under terms of the
financing, a total of 4,860,244 common shares (the "Common Shares") of
Immunovaccine were sold at a price of $0.33 per Common Share.


Net proceeds from the financing will be used to fund preclinical research and
development efforts in the areas of infectious diseases, including respiratory
syncytial virus ("RSV"), malaria and anthrax. These ongoing efforts will support
Immunovaccine's Phase I clinical trials for these infectious diseases programs.
The proceeds will also support preparatory work to advance IMV's clinical stage
oncology program, DPX-Survivac, into Phase II development, as well as ongoing
efforts to establish alliances, collaborations and strategic transactions with
parties including government entities, academic medical centers and other
companies in order to secure additional financing to advance its current
clinical programs and to expand its pipeline of strategic assets.


In connection with the private placement, Immunovaccine will pay a finder's fee
of 4% of a portion of the gross proceeds. The total amount of the finder's fee
is $15,708, payable through the issuance of Common Shares at a deemed price of
$0.33 per Common Share. The Common Shares issued in connection with the
non-brokered private placement (including the Common Shares issued in payment of
the finder's fee) may not be traded until July 6, 2013.


The securities described herein have not been, and will not be, registered under
the United States Securities Act of 1933, as amended (the "U.S. Securities
Act"), or any state securities laws, and accordingly, may not be offered or sold
within the United States except in compliance with the registration requirements
of the U.S. Securities Act and applicable state securities requirements or
pursuant to exemptions therefrom. This press release does not constitute an
offer to sell or a solicitation to buy any securities in any jurisdiction.


About Immunovaccine

Immunovaccine Inc. applies its novel adjuvanting platform to the development of
vaccines for cancer therapy, infectious diseases and animal health. The
Company's DepoVax(TM) platform is a patented formulation that provides
controlled and prolonged exposure of antigens plus adjuvant to the immune
system. Immunovaccine has advanced two DepoVax-based cancer vaccines into Phase
I human clinical trials. The Company is also advancing a broad infectious
disease pipeline including vaccines in such indications as malaria, respiratory
syncytial virus (RSV) and anthrax. In addition to the Company's human health
vaccine strategy, it continues to capture value from animal health vaccine
applications. Immunovaccine has key partnerships in the animal health sector
including an agreement with Pfizer Animal Health. Connect at www.imvaccine.com.


This press release contains forward-looking information under applicable
securities law. All information that addresses activities or developments that
we expect to occur in the future, including information regarding the use of
proceeds of the financing, is forward-looking information. Forward-looking
statements are based on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a representation
that any of the plans will be achieved. Actual results may differ materially
from those set forth in this press release due to risks affecting the company,
including access to capital, the successful completion of clinical trials and
receipt of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press release except
as required by law.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Immunovaccine Inc.
Kimberly Stephens
(902) 492-1819
kstephens@imvaccine.com
www.imvaccine.com


Vida Strategic Partners (media)
Tim Brons
(415) 675-7402
tbrons@vidasp.com

Resolve Ventures (TSXV:RSV)
Historical Stock Chart
From Oct 2024 to Nov 2024

Resolve Ventures (TSXV:RSV)
Historical Stock Chart
From Nov 2023 to Nov 2024